A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials
Authors
Keywords
-
Journal
Biomarkers in Medicine
Volume 8, Issue 6, Pages 893-911
Publisher
Future Medicine Ltd
Online
2014-09-16
DOI
10.2217/bmm.14.14
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide
- (2015) Urban Emmenegger et al. NEOPLASIA
- A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy
- (2014) Rebekka Kubisch et al. Translational Oncology
- Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?
- (2013) Klas Norrby APMIS
- Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: The CASA randomized trial
- (2013) Diana Crivellari et al. BREAST
- VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
- (2013) P Orlandi et al. BRITISH JOURNAL OF CANCER
- A phase 1 trial of imatinib, bevacizumab and metronomic cyclophosphamide in advanced colorectal cancer
- (2013) R K Kelley et al. BRITISH JOURNAL OF CANCER
- Metronomic chemotherapy for cancer treatment: a decade of clinical studies
- (2013) Adriana Romiti et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Predictive Biomarkers for Bevacizumab: Are We There Yet?
- (2013) D. Maru et al. CLINICAL CANCER RESEARCH
- Low-dose metronomic chemotherapy: A systematic literature analysis
- (2013) K. Lien et al. EUROPEAN JOURNAL OF CANCER
- Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
- (2013) Marta Vives et al. INTERNATIONAL JOURNAL OF CANCER
- Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy
- (2013) Annabelle Chow et al. INVESTIGATIONAL NEW DRUGS
- Has the time come for metronomics in low-income and middle-income countries?
- (2013) Nicolas André et al. LANCET ONCOLOGY
- A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer
- (2013) Nathan J. Robison et al. PEDIATRIC BLOOD & CANCER
- Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
- (2012) Giacomo Allegrini et al. ANGIOGENESIS
- FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial
- (2012) S. Ladoire et al. ANNALS OF ONCOLOGY
- Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab
- (2012) Silvia Dellapasqua et al. BREAST
- Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity
- (2012) Emilia Montagna et al. Clinical Breast Cancer
- Clinical value of circulating endothelial cell detection in oncology
- (2012) Jaco Kraan et al. DRUG DISCOVERY TODAY
- Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer
- (2012) David Loven et al. DRUG DISCOVERY TODAY
- Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy
- (2012) Mariana S. Nars et al. INTERNATIONAL JOURNAL OF CANCER
- Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α
- (2012) Yeo-Jung Kim et al. INTERNATIONAL JOURNAL OF CANCER
- Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts
- (2012) Ines Martin-Padura et al. LABORATORY INVESTIGATION
- Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma
- (2012) Yu-Yun Shao et al. ONCOLOGY
- Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy
- (2011) Manuela Miscoria et al. ANTI-CANCER DRUGS
- Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis
- (2011) PER ALBERTSSON et al. APMIS
- Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
- (2011) Charlotte M Huijts et al. BMC CANCER
- Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
- (2011) O A Khan et al. BRITISH JOURNAL OF CANCER
- Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1 in Advanced Solid Tumors
- (2011) S. Kummar et al. CLINICAL CANCER RESEARCH
- Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil
- (2011) Chao-Yu Hsu et al. JOURNAL OF HEPATOLOGY
- A Phase II Randomized Trial of Gefitinib Alone or with Tegafur/Uracil Treatment in Patients with Pulmonary Adenocarcinoma Who had Failed Previous Chemotherapy
- (2011) Yuh-Min Chen et al. Journal of Thoracic Oncology
- Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial
- (2011) B. Walter et al. MEDICAL ONCOLOGY
- Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
- (2011) Vincenzo Cerullo et al. MOLECULAR THERAPY
- High Circulating Endothelial Progenitor Levels Associated with Poor Survival of Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Combined with Metronomic Chemotherapy
- (2011) Yu-Yun Shao et al. ONCOLOGY
- Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo
- (2010) KLAS NORRBY et al. APMIS
- Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis
- (2010) A. Zaslavsky et al. BLOOD
- A phase 2 pilot trial of low-dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma
- (2010) Rupal S. Bhatt et al. CANCER
- Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma
- (2010) Jia Ruan et al. CANCER
- Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy
- (2010) Amélie Lansiaux et al. INVESTIGATIONAL NEW DRUGS
- In vivo chemoresistance of prostate cancer in metronomic cyclophosphamide therapy
- (2010) Lilja Thoenes et al. Journal of Proteomics
- METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION-RESISTANT PROSTATE CANCER
- (2010) Andrea Fontana et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Metronomic chemotherapy: new rationale for new directions
- (2010) Eddy Pasquier et al. Nature Reviews Clinical Oncology
- Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network
- (2009) Maria P Brizzi et al. BMC CANCER
- Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
- (2009) D A Reardon et al. BRITISH JOURNAL OF CANCER
- Classification of Chemotherapeutic Agents Based on Their Differential In vitro Effects on Dendritic Cells
- (2009) H. Tanaka et al. CANCER RESEARCH
- Dual Therapeutic Efficacy of Vinblastine as a Unique Chemotherapeutic Agent Capable of Inducing Dendritic Cell Maturation
- (2009) H. Tanaka et al. CANCER RESEARCH
- Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients
- (2009) D. Generali et al. CLINICAL CANCER RESEARCH
- Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer
- (2009) A. Fontana et al. CLINICAL CANCER RESEARCH
- Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer
- (2009) E. Briasoulis et al. CLINICAL CANCER RESEARCH
- Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab
- (2009) A. Calleri et al. CLINICAL CANCER RESEARCH
- Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer
- (2009) Anna Fioravanti et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Regulation of Vascular Endothelial Growth Factor (VEGF) Splicing from Pro-angiogenic to Anti-angiogenic Isoforms
- (2009) Dawid G. Nowak et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Oral Uracil and Tegafur Compared With Classic Cyclophosphamide, Methotrexate, Fluorouracil As Postoperative Chemotherapy in Patients With Node-Negative, High-Risk Breast Cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial
- (2009) Toru Watanabe et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of Response
- (2009) Nan Soon Wong et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers of response and resistance to antiangiogenic therapy
- (2009) Rakesh K. Jain et al. Nature Reviews Clinical Oncology
- Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells
- (2009) K. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab
- (2008) A. M. Schultheis et al. CLINICAL CANCER RESEARCH
- Down-Regulation of Phosphatidylinositol 3'-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer
- (2008) D. Generali et al. CLINICAL CANCER RESEARCH
- Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
- (2008) Silvia Dellapasqua et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphorylated ERα, HIF-1α, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer
- (2008) Daniele Generali et al. JOURNAL OF CLINICAL ONCOLOGY
- Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients
- (2007) David Loven et al. ACTA ONCOLOGICA
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started